Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$43.41

2.48 (6.06%)

09:14
07/22/17
07/22
09:14
07/22/17
09:14

Upbeat sales news, guidance boost lift Sarepta shares, Barron's reports

Sarepta's shares surged last week after the company reported stronger than expected U.S. sales of its drug for Duchenne muscular dystrophy, or DMD, in the second quarter, while raising sales guidance for the year, Andrew Bary writes in this week's edition of Barron's. There could be more upside in the shares because of the significant sales potential for its DMD drug, Exondys 51, the report noted, adding that Sarepta looks like one of the "most promising smaller biotech companies."Reference Link

SRPT Sarepta
$43.41

2.48 (6.06%)

07/20/17
RHCO
07/20/17
NO CHANGE
RHCO
Sarepta price target raised to $56 from $45 at SunTrust
SunTrust analyst Edward Nash raised his price target on Sarepta (SRPT) after Sarepta and BioMarin (BMRN) executed a license agreement that provides Sarepta Therapeutics with global exclusive rights to BioMarin's DMD patent estate for EXONDYS 51 and all future exon-skipping products. The analyst says that EXONDYS 51 "continued to demonstrate strong momentum" in Q2, and he keeps a Buy rating on Sarepta.
07/20/17
COWN
07/20/17
NO CHANGE
Target $69
COWN
Outperform
Sarepta price target raised to $69 from $62 at Cowen
Cowen analyst Ritu Baral raised her price target on Sarepta to $69 from $62 following Q2 results. The analyst noted results were solid and the company raised its sales guidance for Exondys 51 and sees it on track for a first half 2018 EU decision. She sees longer-term value in the company's maturing pipeline with multiple readouts expected by year-end. Baral reiterated her Outperform rating on Sarepta shares.
07/20/17
NEED
07/20/17
NO CHANGE
Target $75
NEED
Buy
Sarepta guidance still 'too conservative,' says Needham
Needham analyst Chad Messer notes that Sarepta reported Q2 Exondys revenues of $35M, significantly beating Street expectations, and again raised guidance for 2017 from above $95M to $125M-130M, a level he still views as conservative. The analyst now sees Sarepta achieving profitability as early as Q2 of 2018. He reiterates a Buy rating and $75 price target on the shares.
07/20/17
LEER
07/20/17
NO CHANGE
Target $60
LEER
Outperform
Sarepta price target raised to $60 from $52 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Sarepta to $60 from $52 as "strong" Exondys51 sales in Q2 handily beat estimates leading to yet another revised 2017 guidance. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

PHI

PLDT

$22.86

-0.44 (-1.89%)

15:35
11/20/18
11/20
15:35
11/20/18
15:35
Downgrade
PLDT rating change  »

PLDT downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$46.40

-2.39 (-4.90%)

15:34
11/20/18
11/20
15:34
11/20/18
15:34
Options
Foot Locker options imply 17.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

BAYRY

Bayer

$0.00

(0.00%)

15:19
11/20/18
11/20
15:19
11/20/18
15:19
Hot Stocks
Bayer granted FDA orphan designation for Hemophilia A treatment »

Bayer was granted FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BILI

Bilibili

$13.68

0.65 (4.99%)

15:19
11/20/18
11/20
15:19
11/20/18
15:19
Options
Bilibili options imply 19.2% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
11/20/18
11/20
15:17
11/20/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XENE

Xenon Pharmaceuticals

$8.18

0.12 (1.49%)

15:16
11/20/18
11/20
15:16
11/20/18
15:16
Hot Stocks
Xenon granted orphan designation for alternating hemiplegia treatment »

Xenon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
11/20/18
11/20
15:16
11/20/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCG

Scana

$44.14

0.44 (1.01%)

, D

Dominion

$74.55

0.15 (0.20%)

15:12
11/20/18
11/20
15:12
11/20/18
15:12
Hot Stocks
Scana higher as Dominion offers alternate deal plan to South Carolina PSC »

According to a new filing…

SCG

Scana

$44.14

0.44 (1.01%)

D

Dominion

$74.55

0.15 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACHN

Achillion

$2.89

0.11 (3.96%)

15:10
11/20/18
11/20
15:10
11/20/18
15:10
Options
Second day of call buying in Achillion Pharma »

Second day of call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NXRT

NexPoint Residential

$36.26

0.93 (2.63%)

15:06
11/20/18
11/20
15:06
11/20/18
15:06
Hot Stocks
NexPoint Residential VP Matt McGraner buys over $313K in company shares »

NexPoint Residential VP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMWYY

BMW

$0.00

(0.00%)

, DDAIF

Daimler AG

$0.00

(0.00%)

15:04
11/20/18
11/20
15:04
11/20/18
15:04
Periodicals
Trump plans talks with German car executives, Bloomberg says »

The White House has…

BMWYY

BMW

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

VLKAY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$24.91

-0.535 (-2.10%)

15:04
11/20/18
11/20
15:04
11/20/18
15:04
Options
Gap options imply 11.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Mar

D

Dominion

$74.65

0.25 (0.34%)

, SCG

Scana

$44.08

0.38 (0.87%)

15:01
11/20/18
11/20
15:01
11/20/18
15:01
Periodicals
Dominion proposes alternate plan for Scana deal, Bloomberg says »

Bloomberg cites an…

D

Dominion

$74.65

0.25 (0.34%)

SCG

Scana

$44.08

0.38 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USO

United States Oil Fund

$11.27

-0.865 (-7.13%)

15:00
11/20/18
11/20
15:00
11/20/18
15:00
Options
Active trading in US Oil Fund options as crude oil drops 7% »

Active trading in US Oil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
11/20/18
11/20
15:00
11/20/18
15:00
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

HIMX

Himax

$4.05

-0.075 (-1.82%)

14:56
11/20/18
11/20
14:56
11/20/18
14:56
Downgrade
Himax rating change  »

Himax downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 04

    Dec

  • 05

    Dec

14:55
11/20/18
11/20
14:55
11/20/18
14:55
General news
U.S. Durable Goods Preview »

U.S. Durable Goods…

14:55
11/20/18
11/20
14:55
11/20/18
14:55
General news
U.S. Existing Home Sales Preview »

U.S. Existing Home Sales…

14:55
11/20/18
11/20
14:55
11/20/18
14:55
General news
U.S. Michigan Consumer Sentiment Preview »

U.S. Michigan Consumer…

14:55
11/20/18
11/20
14:55
11/20/18
14:55
General news
U.S. Leading Indicators Preview »

U.S. Leading Indicators…

FB

Facebook

$131.60

-0.02 (-0.02%)

14:53
11/20/18
11/20
14:53
11/20/18
14:53
Periodicals
Dashboard to track time wasted on Facebook starts roll out, Venture Beat says »

Facebook has confirmed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

HIMX

Himax

$4.05

-0.075 (-1.82%)

14:52
11/20/18
11/20
14:52
11/20/18
14:52
Downgrade
Himax rating change  »

Himax downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 04

    Dec

  • 05

    Dec

XRT

S&P Retail Index SPDR

$44.32

-1.2 (-2.64%)

14:50
11/20/18
11/20
14:50
11/20/18
14:50
Options
SPDR Retail Trust options are active ahead of Black Friday »

SPDR Retail Trust options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADSK

Autodesk

$122.41

-3.34 (-2.66%)

14:49
11/20/18
11/20
14:49
11/20/18
14:49
Options
Autodesk options imply 12.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 26

    Nov

  • 04

    Dec

EQT

EQT Corporation

$16.81

-0.25 (-1.47%)

14:45
11/20/18
11/20
14:45
11/20/18
14:45
Options
EQT Corporation call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.